SCHEMBL2352069

SCHEMBL2352069

O=C1c2ccccc2CN1N1CCNCC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.65
▸ HTR2C P28335 7/20 0.47
▸ HTR2B P41595 7/20 0.47
▸ HTR2A P28223 7/20 0.47
▸ NPC1 O15118 3/20 0.45
▸ RAB9A P51151 3/20 0.45
▸ PKM P14618 2/20 0.41
▸ HTR1A P08908 1/20 0.40
▸ HTR7 P34969 1/20 0.40
▸ HTR5A P47898 1/20 0.40
▸ HTR6 P50406 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.39
▸ ALOX15 P16050 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ SIRT1 Q96EB6 1/20 0.39
▸ CRBN Q96SW2 1/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ XIAP P98170 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11355286 0.83 KMT2A (0.69) KMT2AHTR2CNPC1RAB9APKM
SCHEMBL14352086 0.80 KMT2A (0.65) KMT2ANPC1RAB9APKMHTR1A
Diftalone SCHEMBL35351 0.80 KMT2A (1.00) KMT2ANPC1RAB9APKMKDM4E
Diftalone SCHEMBL29644941 0.80 KMT2A (1.00) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL2343942 0.76 KMT2A (0.59) KMT2ANPC1RAB9APKMHTR1A
SCHEMBL21802156 0.73 POLB (0.45) HTR2CHTR2BHTR2AHTR1AHTR7
SCHEMBL30550377 0.72 NPC1 (0.64) KMT2ANPC1RAB9APKMHTR1A
SCHEMBL31331343 0.71 KMT2A (0.66) KMT2AHTR2CHTR2BHTR2ANPC1
SCHEMBL16868889 0.71 DRD2 (0.55) NPC1RAB9AHTR1AHTR7KDM4E
Diftalone SCHEMBL8196066 0.70 KMT2A (0.78) KMT2ANPC1RAB9APKMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445514-B2 Urotensin II receptor antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2013-05-21 — — US disclosed
US-20110269768-A1 UROTENSIN II RECEPTOR ANTAGONISTS KINNEY WILLIAM A 2011-11-03 — — US disclosed
US-8008299-B2 Urotensin II receptor antagonists JANSSEN PHARMACEUTICA, N.V. (FR) 2011-08-30 — — US disclosed
US-20080318973-A1 Urotensin II receptor antagonists JANSSEN PHARMACEUTICA, N.V. (BE) 2008-12-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269768-A1 UROTENSIN II RECEPTOR ANTAGONISTS UTS2R, BDKRB2, AGTR2 KMT2A 2995/4885HTR2C 476/4885HTR2B 286/4885
US-20080318973-A1 Urotensin II receptor antagonists UTS2R, BDKRB2, AGTR2 KMT2A 2995/4885HTR2C 476/4885HTR2B 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback